Christopher Moore

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 9

Top Venues

Cancer research

Science translational medicine

Science advances

Francis Crick Institute

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Francis Crick Institute

United Kingdom

senior research scientist

Publications

Jesse Boumelha, Andrea de Castro, Nourdine Bah, Hongui Cha, Sophie de Carné Trécesson, Sareena Rana, Mona Tomaschko, Panayiotis Anastasiou, Edurne Mugarza, Christopher Moore, Robert Goldstone, Philip East, Kevin Litchfield, Se-Hoon Lee, Miriam Molina-Arcas, Julian Downward
CRISPR-Cas9 screening identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer. Cancer research (2024)
Jesse Boumelha, Andrea de Castro, Nourdine Bah, Hongui Cha, Sophie de Carné Trécesson, Sareena Rana, Mona Tomaschko, Panayiotis Anastasiou, Edurne Mugarza, Christopher Moore, Robert Goldstone, Philip East, Kevin Litchfield, Se-Hoon Lee, Miriam Molina-Arcas, Julian Downward
CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer. Cancer research 84 (14) (2024)
Jesse Boumelha, Andrea de Castro, Nourdine Bah, Hongui Cha, Sophie de Carné Trécesson, Sareena Rana, Mona Tomaschko, Panayiotis Anastasiou, Edurne Mugarza, Christopher Moore, Robert Goldstone, Philip East, Kevin Litchfield, Se-Hoon Lee, Miriam Molina-Arcas, Julian Downward
CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer. Cancer research 84 (14) (2024)
Jesse Boumelha, Andrea de Castro, Nourdine Bah, Hongui Cha, Sophie de Carné Trécesson, Sareena Rana, Mona Tomaschko, Panayiotis Anastasiou, Edurne Mugarza, Christopher Moore, Robert Goldstone, Philip East, Kevin Litchfield, Se-Hoon Lee, Miriam Molina-Arcas, Julian Downward
CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer. Cancer research 84 (14) (2024)
Jesse Boumelha, Sophie de Carné Trécesson, Emily K Law, Pablo Romero-Clavijo, Matthew A Coelho, Kevin W Ng, Edurne Mugarza, Christopher Moore, Sareena Rana, Deborah R Caswell, Miguel Murillo, David C Hancock, Prokopios P Argyris, William L Brown, Cameron Durfee, Lindsay K Larson, Rachel Isaksson Vogel, Alejandro Suarez-Bonnet, Simon Lawrence Priestnall, Philip East, Sarah J Ross, George Kassiotis, Miriam Molina-Arcas, Charles Swanton, Reuben Stewart Harris, Julian Downward
An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations. Cancer research 82 (19) (2022)
Edurne Mugarza, Febe van Maldegem, Jesse Boumelha, Christopher Moore, Sareena Rana, Miriam Llorian Sopena, Philip East, Rachel Ambler, Panayiotis Anastasiou, Pablo Romero-Clavijo, Karishma Valand, Megan Cole, Miriam Molina-Arcas, Julian Downward
Therapeutic KRAS G12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. Science advances 8 (29) (2022)
Stelios Chrysostomou, Rajat Roy, Filippo Prischi, Lucksamon Thamlikitkul, Kathryn L Chapman, Uwais Mufti, Robert L Peach, Laifeng Ding, David C Hancock, Christopher Moore, Miriam Molina-Arcas, Francesco Mauri, David James Pinato, Joel M Abrahams, Silvia Ottaviani, Castellano L, Georgios Giamas, Jennifer Pascoe, Devmini Moonamale, Sarah J Pirrie, Claire Gaunt, Lucinda Billingham, Neil M Steven, Michael Cullen, David Hrouda, Mathias Winkler, John Post, Philip Cohen, Seth J Salpeter, Vered Bar, Adi Zundelevich, Shay Golan, Dan Leibovici, Romain Lara, David R Klug, Sophia N Yaliraki, Mauricio Barahona, Yulan Wang, Julian Downward, J Mark Skehel, Maruf M U Ali, Michael J Seckl, Olivier E Pardo
Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer. Science translational medicine 13 (602) (2021)
Miriam Molina-Arcas, Christopher Moore, Sareena Rana, Febe van Maldegem, Edurne Mugarza, Pablo Romero-Clavijo, Eleanor Herbert, Stuart Horswell, Lian-Sheng Li, Matthew R Janes, David C Hancock, Julian Downward
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. Science translational medicine 11 (510) (2020)
Hanna Foster, E Josue Ruiz, Christopher Moore, Gordon W H Stamp, Emma L Nye, Ningning Li, Yihang Pan, Yulong He, Julian Downward, Axel Behrens
ATMIN Is a Tumor Suppressor Gene in Lung Adenocarcinoma. Cancer research 79 (20) (2019)

Christopher Moore.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Christopher Moore